Changing Haemophilia is Novo Nordisk's commitment to address the
unmet needs in haemophilia care, beyond medicine.
Haemophilia is a rare and serious disease affecting approx. 1 out of
10,000 people around the world. Many people with haemophilia are still
undiagnosed or inadequately treated. Even when treated, people may
suffer from chronic pain and limited mobility mainly due to bleeds in
the joints, and if undertreated or not treated at all, risk dying at a
Since Novo Nordisk was founded more than 90 years ago, we have been
driving change to defeat chronic conditions. This includes three
decades of improving lives of people with haemophilia through support
to improved diagnosis, treatment and care.
Our key contribution is to discover and develop effective and safe
medicines for people with haemophilia and other rare bleeding
disorders. We offer a broad and innovative range of products and have
a rich research/development pipeline to ensure we are in the forefront
of finding the next generation of medicines.
But to truly change haemophilia, we need to do more than supply the right medicines. With our Changing Haemophilia® commitment we aim to address the unmet needs in haemophilia. Together with our community partners, we work to advocate for, and create better access to, diagnosis and multidisciplinary care. We aim for better joint health and mobility including a strong focus on well-being for people living with haemophilia.
We work towards a future where everyone with Haemophilia is
diagnosed. and can live a life with as few limitations as